2,000 Shares in Tempus AI, Inc. $TEM Purchased by Trifecta Capital Advisors LLC

Trifecta Capital Advisors LLC bought a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) during the 2nd quarter, Holdings Channel.com reports. The firm bought 2,000 shares of the company’s stock, valued at approximately $127,000.

Several other large investors have also recently added to or reduced their stakes in TEM. Cherry Tree Wealth Management LLC purchased a new position in Tempus AI during the first quarter worth about $31,000. University of Texas Texas AM Investment Management Co. purchased a new position in Tempus AI during the first quarter worth about $33,000. Continuum Advisory LLC purchased a new position in Tempus AI during the first quarter worth about $39,000. Bartlett & CO. Wealth Management LLC lifted its position in Tempus AI by 100.0% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 800 shares of the company’s stock worth $39,000 after buying an additional 400 shares during the period. Finally, Nemes Rush Group LLC acquired a new stake in Tempus AI during the first quarter worth about $39,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Eric P. Lefkofsky sold 332,500 shares of the stock in a transaction dated Thursday, September 25th. The stock was sold at an average price of $76.56, for a total value of $25,456,200.00. Following the completion of the sale, the chief executive officer owned 9,141,032 shares in the company, valued at approximately $699,837,409.92. This trade represents a 3.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Ryan Fukushima sold 5,000 shares of the stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $92.32, for a total value of $461,600.00. Following the completion of the sale, the chief operating officer owned 130,000 shares of the company’s stock, valued at approximately $12,001,600. This trade represents a 3.70% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 933,662 shares of company stock valued at $68,070,993. Company insiders own 26.27% of the company’s stock.

Tempus AI Price Performance

TEM stock opened at $103.25 on Thursday. The company has a debt-to-equity ratio of 2.58, a quick ratio of 1.43 and a current ratio of 1.54. Tempus AI, Inc. has a 1 year low of $31.36 and a 1 year high of $103.42. The firm has a market cap of $17.94 billion, a P/E ratio of -86.76 and a beta of 4.87. The stock has a 50-day simple moving average of $77.21 and a 200-day simple moving average of $64.16.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The business had revenue of $314.64 million during the quarter, compared to analyst estimates of $296.84 million. During the same quarter last year, the firm earned ($6.86) earnings per share. The company’s revenue for the quarter was up 89.5% compared to the same quarter last year. Tempus AI has set its FY 2025 guidance at EPS. On average, equities analysts predict that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. BTIG Research upped their price target on Tempus AI from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday, August 20th. HC Wainwright upped their price target on Tempus AI from $90.00 to $98.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Bank of America upped their price target on Tempus AI from $68.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday, June 25th. Morgan Stanley upped their price target on Tempus AI from $65.00 to $68.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 12th. Finally, Guggenheim upped their price target on Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, September 26th. Seven equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Tempus AI has a consensus rating of “Hold” and an average target price of $71.83.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.